AbbVie to Acquire Landos Biopharma, Further Strengthening Its Portfolio in Inflammatory and Autoimmune Diseases

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) announce a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair. NLRX1 regulates immunometabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis.

Read the full article: AbbVie to Acquire Landos Biopharma, Further Strengthening Its Portfolio in Inflammatory and Autoimmune Diseases //

Source: https://www.prnewswire.com/news-releases/abbvie-to-acquire-landos-biopharma-further-strengthening-its-portfolio-in-inflammatory-and-autoimmune-diseases-302098124.html

Leave a Comment

Your email address will not be published.

Scroll to Top